Answers are grounded in this paper and cite their sources.
The study met its primary end point, demonstrating activity of regorafenib in patients with progressive metastatic osteosarcoma. No new safety signals were observed. Regorafenib should be considered a treatment option for patients with relapsed metastatic osteosarcoma.
No takes yet. Share an insight, caveat, or question.
Davis et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: